{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:07:32Z","timestamp":1760044052229,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.pharma.2015.04.002","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T20:48:27Z","timestamp":1431550107000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Forced degradation studies, and effect of surfactants and titanium dioxide on the photostability of paliperidone by HPLC"],"prefix":"10.1016","volume":"73","author":[{"given":"V.K.","family":"Marothu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nellutla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gorrepati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Majeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Mamidala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2015.04.002_bib0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended release tablets: A 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.pharma.2015.04.002_bib0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended\u2212release tablets for prevention of symptom recurrence in patients with schizophrenia","volume":"27","author":"Kramer","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharma.2015.04.002_bib0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4088\/JCP.v65n0121","article-title":"Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics","volume":"65","author":"Keith","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pharma.2015.04.002_bib0215","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","article-title":"Biochemical profile of risperidone, a new antipsychotic","volume":"247","author":"Leysen","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl.","key":"10.1016\/j.pharma.2015.04.002_bib0220","first-page":"5","article-title":"Risperidone: a novel antipsychotic with balanced serotonin dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"Leysen","year":"1994","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pharma.2015.04.002_bib0225","first-page":"48","article-title":"Available guidance and best practices for conducting forced degradation studies","volume":"26","author":"Reynolds","year":"2002","journal-title":"Pharm Technol"},{"issue":"2","key":"10.1016\/j.pharma.2015.04.002_bib0230","first-page":"48","article-title":"Toward a generic approach for stress testing of drug substances and drug products","volume":"29","author":"Klick","year":"2005","journal-title":"Pharm Technol"},{"issue":"3","key":"10.1016\/j.pharma.2015.04.002_bib0235","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs\u2013A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.pharma.2015.04.002_bib0240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2013.09.031","article-title":"A novel bi-layer ascending release osmotic pump tablet: in vitro investigation and in vivo investigation in pharmacokinetic study and IVIVC evaluation","volume":"458","author":"Xu","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2015.04.002_bib0245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0378-4347(92)80556-6","article-title":"Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high performance liquid chromatography","volume":"583","author":"Woestenborghs","year":"1992","journal-title":"J Chromatogr"},{"key":"10.1016\/j.pharma.2015.04.002_bib0250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0378-4347(93)80327-Z","article-title":"Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection","volume":"614","author":"Le Moing","year":"1993","journal-title":"J Chromatogr"},{"key":"10.1016\/j.pharma.2015.04.002_bib0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-4347(00)00323-6","article-title":"Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection","volume":"746","author":"Avenoso","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.pharma.2015.04.002_bib0260","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2007-979308","article-title":"Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection","volume":"31","author":"Aravagiri","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharma.2015.04.002_bib0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0378-4347(97)00302-2","article-title":"Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs","volume":"698","author":"Olesen","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.pharma.2015.04.002_bib0270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jssc.200401939","article-title":"HPLC-DAD determination of plasma levels of the antipsychotic risperidone and its main metabolite for toxicological purposes","volume":"28","author":"Raggi","year":"2005","journal-title":"J Sep Sci"},{"key":"10.1016\/j.pharma.2015.04.002_bib0275","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/elps.201100328","article-title":"Enantioselective fungal biotransformation of risperidone in liquid culture medium by capillary electrophoresis and hollow fiber liquid-phase microextraction","volume":"32","author":"de Jesus","year":"2011","journal-title":"Electrophoresis"},{"key":"10.1016\/j.pharma.2015.04.002_bib0280","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchromb.2008.04.041","article-title":"Validated LC-MS\/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine","volume":"870","author":"Meulder","year":"2008","journal-title":"J Chromatogr B"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2015.04.002_bib0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.chroma.2003.10.138","article-title":"Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry","volume":"1026","author":"Flarakos","year":"2004","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.pharma.2015.04.002_bib0290","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.chroma.2007.06.023","article-title":"Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis: validation and determination of enantiomeric purity","volume":"1163","author":"Danel","year":"2007","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.pharma.2015.04.002_bib0295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jchromb.2007.02.007","article-title":"Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS\/MS","volume":"852","author":"Cabovska","year":"2007","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.pharma.2015.04.002_bib0300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jpba.2009.06.013","article-title":"Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection","volume":"50","author":"Locatelli","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2015.04.002_bib0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.aca.2012.05.056","article-title":"Solid phase microextraction and LC\u2013MS\/MS for the determination of paliperidone after stereoselective fungal biotransformation of risperidone","volume":"742","author":"Bocato","year":"2012","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.pharma.2015.04.002_bib0310","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.talanta.2006.10.049","article-title":"Turbulent flow and ternary column-switching on-line clean-up system for high throughput quantification of risperidone and its main metabolite in plasma by LC-MS\/MS: application to a bioequivalence study","volume":"72","author":"Kousoulos","year":"2007","journal-title":"Talanta"},{"key":"10.1016\/j.pharma.2015.04.002_bib0315","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1570-0232(02)00715-8","article-title":"Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry","volume":"783","author":"Remmerie","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.pharma.2015.04.002_bib0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jchromb.2012.09.009","article-title":"Liquid chromatography\u2013tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum","volume":"907","author":"U\u0159inovsk\u00e1","year":"2012","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.pharma.2015.04.002_bib0325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.chroma.2012.12.071","article-title":"Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring","volume":"1292","author":"Ansermot","year":"2013","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.pharma.2015.04.002_bib0330","first-page":"286","article-title":"Development and validation of a rapid and sensitive UHPLC-MS\/MS method for the determination of paliperidone in beagle dog plasma","volume":"9","author":"Chen","year":"2014","journal-title":"Asian J Pharmaceutical Sci"},{"key":"10.1016\/j.pharma.2015.04.002_bib0335","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.107.018275","article-title":"Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans","volume":"36","author":"Vermeir","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharma.2015.04.002_bib0340","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/chromsci\/bms011","article-title":"A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in paliperidone active pharmaceutical ingredient and its pharmaceutical dosage forms","volume":"50","author":"Hima Bindu","year":"2012","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.pharma.2015.04.002_bib0345","first-page":"10","article-title":"Stress degradation behaviour of paliperidone, an antipsychotic drug, and development of suitable stability-indicating RP-LC method","author":"Jadhav","year":"2011","journal-title":"Chromatogr Res Int"},{"key":"10.1016\/j.pharma.2015.04.002_bib0350","first-page":"39","article-title":"Identification and characterization of forced degradation products of paliperidone using LC-APCI-Ion Trap-MS","volume":"6","author":"Sawant","year":"2013","journal-title":"J Pharm Res"},{"key":"10.1016\/j.pharma.2015.04.002_bib0355","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.powtec.2013.05.042","article-title":"Using spray-dried lactose monohydrate in wet granulation method for a low-dose oral formulation of a paliperidone derivative","volume":"246","author":"Huang","year":"2013","journal-title":"Powder Technol"},{"year":"2002","series-title":"Surfactants and polymers in drug delivery","author":"Malmsten","key":"10.1016\/j.pharma.2015.04.002_bib0360"},{"issue":"3","key":"10.1016\/j.pharma.2015.04.002_bib0365","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/jps.10575","article-title":"Effect of relative humidity on the photocatalytic activity of titanium dioxide and photostability of famotidine","volume":"93","author":"Kakinoki","year":"2004","journal-title":"J Pharm Sci"},{"year":"2005","series-title":"Validation of analytical procedures: text and methodology, in: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use, Q2(R1)","key":"10.1016\/j.pharma.2015.04.002_bib0370"},{"issue":"1","key":"10.1016\/j.pharma.2015.04.002_bib0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jscs.2011.05.017","article-title":"Effect of reactive and non-reactive counterion micelles upon the alkaline degradation of indomethacin","volume":"18","author":"Al-Ayed","year":"2014","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.pharma.2015.04.002_bib0380","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcis.2011.05.005","article-title":"Effect of alkyl chain length, head group and nature of the surfactant on the hydrolysis of 1,3-benzoxazine-2,4- dione and its derivatives","volume":"361","author":"Al-Ayed","year":"2011","journal-title":"J Colloid Interf Sci"},{"key":"10.1016\/j.pharma.2015.04.002_bib0385","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/j.watres.2010.02.039","article-title":"Recent developments in photocatalytic water treatment technology: a review","volume":"44","author":"Chong","year":"2010","journal-title":"Water Res"},{"year":"2001","series-title":"Hand book of modern pharmaceutical analysis, Vol III","author":"Ahuja","key":"10.1016\/j.pharma.2015.04.002_bib0390"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450915000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450915000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:31:27Z","timestamp":1757719887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450915000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0003450915000449"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2015.04.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Forced degradation studies, and effect of surfactants and titanium dioxide on the photostability of paliperidone by HPLC","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2015.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}